Bausch + Lomb (BLCO.TO) traded 3.2% higher in U.S. pre-market trading on Wednesday after reporting fourth-quarter adjusted profit and revenue that beat expectations.
Fourth-quarter adjusted profit rose to US$89 million, or US$0.25 per adjusted share, from US$83 million, or US$0.24 per adjusted share in the prior year period. The result beat the FactSet consensus estimate of US$0.23.
Revenue increased 9%, to US$1.28 billion, above the FactSet estimate of US$1.26 billion. The company reported double-digit revenue growth in the contact lens category, and also grew its surgical portfolio across all product categories in the fourth quarter
Bausch + Lomb expects full year 2025 revenue to range between US$4.95 billion to US$5.05 billion. The FactSet estimate is for US$5.02 billion.
"Underpinning our recent success is a commitment to long-term, profitable growth," said Brent Saunders, chairman and CEO, Bausch + Lomb. "Our refocused pipeline is now filled with promise and potential to significantly enhance the standard of care for patients across the spectrum of eye health needs."
The company's shares were last seen up US$0.52, to US$16.87, in New York trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.